TrialJournal of neurology, neurosurgery, and psychiatry2024

Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study.

Luis Querol et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.